TD Cowen lowered the firm’s price target on Novavax (NVAX) to $9 from $14 and keeps a Hold rating ... Q3 COVID vaccine revenues missed as expected, given delayed start as the low initial market share ...

yesterday and set a price target of $9.00. Eric Joseph has given his Sell rating due to a combination of factors affecting Novavax’s current and future performance. One major concern is the company’s ...

US stocks were muted on Tuesday as investors were awaiting the key economic data such as inflation and retail sales due later ...

Wall Street's three major indexes closed lower on Tuesday as investors booked some profits from a post-election rally and ...

Shares of Novavax Inc. NVAX slid 6.10% to $8.46 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index COMP falling 0.09% to 19,281.40 ...

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

while analysts had expected a loss of 79 cents a share from revenue of $74 million. Still, the stock plummeted 12% to $7.92 ...

Novavax shares dropped Tuesday morning after the company slashed its full-year outlook when it announced its third-quarter results.

Novavax (NVAX) delivered earnings and revenue surprises of 12.64% and 47.43%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Novavax, Inc. ( NASDAQ: NVAX) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET ...

Novavax reported $85 million in revenues for the quarter, down from $187 million the year prior, and loss per share of $0.76, ...